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Peptides derived from buffalo dairy products possess multiple healthy properties that cannot be exerted as long as they are
encrypted in parent proteins. To evaluate the biological activities of encrypted peptide sequences from buffalo ricotta cheese, we
performed a simulated gastrointestinal (GI) digestion. Chemical and pharmacological characterization of the digest led to the
identification of a novel peptide endowed with antioxidant and antihypertensive action. The GI digest was fractionated by
Semiprep-HPLC, and fractions were tested against reactive oxygen species (ROS) release in an H2O2-treated intestinal epithelial
cell line. UHPLC-PDA-MS/MS analysis revealed the presence of an abundant β-lactoglobulin peptide (BRP2) in the most active
fraction. Pharmacological characterization of BRP2 highlighted its antioxidant activity, involving ROS reduction, nuclear factor
erythroid 2-related factor 2 (Nrf2) activation, and cytoprotective enzyme expression. The bioavailability of BRP2 was evaluated
in intestinal transport studies through a Caco-2 cell monolayer. Equal bidirectional transport and linear permeability indicate
that BRP2 was absorbed mainly through passive diffusion. In addition to its local effects, the BRP2 administration on mouse
mesenteric arteries was able to reduce the angiotensin II-induced vasoconstriction by the Nrf2 nuclear translocation, the
reduction of the active form of Ras-related C3 botulinum toxin substrate 1 (Rac1), and the NADPH oxidase activity. These data
further highlight the role of buffalo ricotta cheese-derived peptides against oxidative stress-related diseases and suggest their
health-promoting potential.
1. Introduction
Food proteins are an important source of bioactive peptides.
These are inactive, since encrypted in their parent sequences,
but turn active when released by fermentation or ripening
during food processing or by digestive enzymes during
gastrointestinal transit [1, 2]. Once released, the bioactive
peptides are able to exert various physiological effects
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beneficial for human health [3]. In particular, bioactive pep-
tides can either have local effects on the digestive tract or be
absorbed through the intestine, playing a physiological role
in tissues [4]. These peptides can exhibit various biological
activities, such as antioxidant, antimicrobial, immunomodu-
latory, antithrombotic, and antihypertensive, depending on
their amino acid sequence [5]. The size of active sequences
may vary from two to twenty amino acid residues, and several
peptides are known to reveal multifunctional properties since
some regions in the primary structure of parent protein, con-
sidered “strategic zones,” contain overlapping sequences [6].
The effect of natural antioxidant peptides on health by
treatment and prevention of numerous diseases is of great
interest nowadays due to their safety, small size, low toxicity,
and high activity in addition to the negative consumer per-
ception about synthetic drugs [7]. This is why food-derived
antioxidant peptides have become an interesting target in
food chemistry. Enhancement of the body’s antioxidant
defense mechanism through dietary supplementation would
seem to be a practical approach to reduce the level of reactive
oxygen species (ROS) [8–10].
ROS are produced in a well-regulated manner to help
maintain homeostasis at the cellular level in the normal
healthy tissues, play an important role as second messengers,
and regulate cellular function by modulating signaling path-
ways [11]. An imbalance in the equilibration of prooxidan-
t/antioxidant status determines oxidative stress, characterized
by damage to cellular macromolecules such as DNA, proteins,
and membrane lipids, by human aging, and by diseases, such
as gastrointestinal (GI) and cardiovascular pathologies [12].
The GI tract is prone to ROS attack as it is accessed by the
outside environment with dietary factors that, together with
resident immune cells and intestinal flora, are potential
sources of ROS.
ROS have been linked with various inflammatory GI
disorders such gastroesophageal reflux disease, gastritis,
enteritis, colitis, and associated cancers as well as pancreatitis
and liver cirrhosis [13]. Several studies demonstrate that
oxidative stress also plays an important role in the pathogene-
sis and development of cardiovascular diseases, including
hypertension, dyslipidemia, diabetes mellitus, atherosclerosis,
myocardial infraction, angina pectoris, and heart failure [14].
In fact, oxidative stress is considered to be the main cause of
endothelial dysfunction leading to cardiovascular complica-
tions, mostly through the reduction of nitric oxide (NO) bio-
availability, which is one of the most important mediators of
the physiological properties of endothelial cells. The increased
production of ROS and decreased NO bioavailability promote
endothelial dysfunction, leading to remodeling, platelet aggre-
gation, loss of vasodilation, inflammation, and smooth muscle
cell growth [15]. An imbalance between NO and ROS has
been observed in patients with hypertension [16].
In order to prevent and counteract some GI pathologies
and cardiovascular diseases, the employment of natural anti-
oxidant molecules is crucial. Dairy products and their
fractions can be considered carriers for the delivery of antiox-
idant peptides. We recently evidenced the antioxidant
properties of buffalo milk dairy products and in particular
buffalo ricotta cheese [17, 18].
In addition, several studies showed the antihypertensive
effect of whey protein as renin-angiotensin-converting
enzyme inhibitors, direct stimulators of endothelial NO,
opioid receptor agonists, or direct inhibitors of endothelin-
1 production, but no studies were described concerning the
hypotensive activity of buffalo whey protein-derived
peptides [19–22].
In this regard, the aim of the present work was to
investigate the release, the intestinal absorption, and the
biological activities of potential antioxidant peptides after
simulated oral intake of buffalo ricotta cheese. After
in vitro gastrointestinal digestion, the sample was sepa-
rated into two fractions that were challenged for its anti-
oxidant properties. The peptidomic workflow led to the
identification of an abundant β-lactoglobulin peptide in the
most active fraction. The effect of this peptide on oxidative
stress induced by H2O2 in the intestinal epithelial cells
(IEC-6) and by angiotensin II in mouse mesenteric arteries
was evaluated, together with its bioavailability.
2. Materials and Methods
2.1. Preparation and Fractionation of Buffalo Ricotta
Gastrointestinal Digest by Semiprep-RP-HPLC. The simu-
lated gastrointestinal digestion of buffalo ricotta cheese was
performed according to Pepe et al. [23]. Briefly, the lyophi-
lized sample was incubated with pepsin at 37°C for 2 h to
pH = 2, and the reaction was stopped by heating the solution
at 95°C for 15min. Then, the gastric digest was incubated
with pancreatin, chymotrypsin, and bile salts at 37°C for 2 h
to pH7.5, and the reaction was stopped bringing the solution
to pH2.
The peptides released after gastrointestinal digestion of
buffalo ricotta cheese were fractionated by semipreparative
reversed-phase liquid chromatography. For the separation,
a Shimadzu Semiprep-HPLC was employed consisting of
two LC-20 AP pumps, a SIL-20 AP autosampler, a fraction
collector FRC-10 A, a UV detector SPD-20 A equipped with
a preparative cell, and a system controller CBM-20 A.
The separation was carried out on a Kinetex™ C18
column (150 × 21:2mm × 5 μm (100Å)), and flow rate
(20mLmin-1), injection volume (5mL (2mgmL-1)), detec-
tion UV (214 and 220nm), and the collection were based
on UV-triggering signal. The optimal mobile phase consisted
of (A) H2O and (B) ACN both acidified by trifluoroacetic
acid 0.1% (v/v). Analysis was performed in gradient elution
as follows: 0.01-5.00min, isocratic to 1% B; 5-40.00min, 1-
35% B; 40-43.00min, 35-95% B; and 43-46.00min, isocratic
to 95% B, and then five minutes for column reequilibration.
The fractions were collected on the basis of their elution
times and thus hydrophobicity. In detail, the fractionation
of peptide digesta led to the collection of two different ali-
quots: fraction I (BRF1), from 10.00min to 20.00min, and
fraction II (BRF2), from 20.00 to 30.00min.
2.2. Peptide Identification in the BRF2. Analyses of the bioac-
tive peptides contained in the BRF2 were performed on a
Shimadzu Nexera UHPLC system coupled online to an
LCMS-IT-TOF mass spectrometer through an ESI source
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(Shimadzu, Kyoto, Japan). Separation of BRF2 was carried
out on an Aeris™ Peptide XB-C18 column
(100 × 2:1mm × 1:7 μm) (Phenomenex, Bologna, Italy).
The flow rate and the column oven temperature were set to
0.5mLmin-1 and 60°C, respectively. The chromatograms
were monitored at 214 and 220nm. The mobile phase for
the analysis of BRF2 consisted of 0.1% (v/v) HCOOH/H2O
(A) and 0.1% (v/v) HCOOH/ACN (B). Analysis was per-
formed in gradient elution as follows: 0.01-45.0min, 0-30%
B; 45-47.00min, 30-95% B; and 47-49.00min, isocratic to
95% B, and then five minutes for column reequilibration.
MS detection was operated in ESI+ mode, and MS/MS
experiments were conducted in data-dependent acquisition;
precursor ions were acquired in the range 300-2000 m/z.
A free trial of PEAKS 7.5 software (Bioinformatics
Solutions Inc., Waterloo, Canada) was employed for
sequence determination. A search was performed using a
database search tool, by searching against the SwissProt/Uni-
Prot database (database Bubalus bubalis release 2017).
2.3. Synthesis and Quantification of Buffalo Ricotta Peptide 2
(BRP2). Synthesis of the analogue peptide was performed
according to the solid phase approach using standard Fmoc
methodology, with a Biotage Initiator+Alstra (Uppsala,
Sweden) automated microwave synthesizer (for detailed
conditions, see Supporting Information Appendix S1).
The quantification of BRP2 in buffalo ricotta digesta and
BRF2 was performed on a Nexera UHPLC system coupled
online to an LCMS-8050 mass spectrometer (Shimadzu,
Kyoto, Japan), equipped with an ESI source operated in
positive mode. MS/MS analysis was conducted in selected
reaction monitoring (SRM), employing the synthetic peptide
as an external standard. Stock solution was prepared in water,
the calibration curve was obtained in a concentration range
of 0.1-125μg L-1 with eight concentration levels, and tripli-
cate injection of each level was run. Peak areas of BRP2 were
plotted against the corresponding concentrations. Linear
regression was used to generate the calibration curve
(y = 0:0004x – 1:5321) with R2 values being ≥0.9998 (see
Supporting Information Appendix S2).
2.4. IEC-6 Cells: Culture, Treatment, and Viability Assay. The
IEC-6 cell line (CRL-1592), derived from normal rat intesti-
nal crypt cells, was purchased from the American Type
Culture Collection (ATCC, Rockville, MD, USA).
These cells were cultured by using Dulbecco’s modified
Eagle’s medium (DMEM) (4 g/L glucose), supplemented
with 10% (v/v) heat-inactivated foetal bovine serum, 1.5 g/L
NaHCO3, 2mM L-glutamine, and 0.1 unitmL
-1 bovine insu-
lin. Cells were used, for the experiments, between the 17th
and 21st passages.
The IEC-6 cells (2 × 104) were plated into 96-multiwell
plates and allowed to adhere. After 24 h, cells were exposed
to BRF1 and BRF2 (50-1.25μgmL-1) and BRP2 (100-1μM),
for 24 h. Cell viability was then assessed using the MTT assay,
as previously reported [24].
2.4.1. Measurement of Intracellular ROS Release. ROS levels
were evaluated by means of the probe 2′,7′-dichlorofluor-
escin-diacetate (H2DCF-DA) [25]. For this experiment,
IEC-6 cells were plated into 24-well plates (8 × 104 cells
/well). After adhesion time of 24 h, cells were then treated
with BRF1 and BRF2 (50-1.25μgmL-1) and with BRP2
(100-1μM), for 1 h, either alone or in the presence of H2O2
(1mM) for further 1 h.
IEC-6 cells were then collected, and a PBS buffer was used
in order to wash them. Subsequently, cells were incubated in
PBS containing H2DCF-DA (10μM), for 15min at 37
°C. A
fluorescence-activated cell sorter (FACSscan; Becton Dickin-
son, Franklin Lakes, NJ, USA) was used for the purpose of
measuring cell fluorescence, and CellQuest software (Becton
Dickinson, Milan, Italy) was employed in order to analyze it.
2.4.2. Immunofluorescence Analysis for Nuclear Factor-Like 2
Activation. IEC-6 cells (2 × 105 cells/well) were seeded on
coverslips in a 12-well plate and treated with BRP2 at
concentration of 50μM for 1 h, both alone and in the
presence of H2O2 (1mM) for further 1 h in order to evaluate
nuclear factor- (erythroid-derived 2) like 2 (Nrf2) activation.
After the cellular treatment, 4% paraformaldehyde in PBS
was used to fix the cells. Then, IEC-6 cells were permeabilized
with 0.1% saponin in PBS. After the blocking made with BSA
and PBS, cells were incubated with a rabbit anti-Nrf2 anti-
body (Santa Cruz Biotechnology, Dallas, TX, USA) for 1 h
at 37°C. The slides were then washed three times with PBS.
After that, a fluorescein-conjugated secondary antibody
(FITC) was added for further 1 h. 4′,6-diamidine-2′-pheny-
lindole dihydrochloride (DAPI) was used for the counter-
staining of nuclei. At the end, coverslips were mounted in
mounting medium. Fluorescent images were taken under
the laser confocal microscope (Leica TCS SP5, Leica, Wetzlar,
Germany) as previously reported [26].
2.4.3. Measurement of Heme Oxygenase 1 (HO-1), NAD(P)H
Quinone Dehydrogenase 1 (NQO1), and Superoxide
Dismutase (SOD) Expression. IEC-6 cells were plated into
96-well plates (1 × 104 cells/well) and allowed to adhere.
After 24 h, cells were treated with BRP2 (100-1μM) for 1 h,
either alone or in the presence of H2O2 (1mM) for further
1 h. After cellular treatment, IEC-6 cells were collected,
washed with PBS, and incubated in fixing solution for
20min and then in Fix Perm Solution for further 30min.
Anti-heme oxygenase 1 (Santa Cruz Biotechnology, Dallas,
TX, USA), anti-NAD(P)H quinone dehydrogenase 1 (Santa
Cruz Biotechnology, Dallas, TX, USA), or anti-superoxide
dismutase (Santa Cruz Biotechnology, Dallas, TX, USA) anti-
bodies were then added. The cells were then treated with the
secondary antibody. A fluorescence-activated cell sorter
(FACSscan; Becton Dickinson, Franklin Lakes, NJ, USA)
was used for the purpose of measuring cell fluorescence,
and CellQuest software (Becton Dickinson, Milan, Italy)
was employed in order to analyze it.
2.5. In Vitro Intestinal Transepithelial Transport Studies
2.5.1. Caco-2 Cell Monolayer Permeation Experiments. The
colorectal adenocarcinoma (Caco-2) cell line was purchased
from ATCC (Rockville, MD, USA). Cells were maintained
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in high-glucose DMEM (4.5 g/L) supplemented with 2mM
L-glutamine and 10% (v/v) heat-inactivated foetal bovine
serum. Cells were cultured at 37°C in a humidified 5% CO2
atmosphere. To induce enterocytic Caco-2 differentiation,
cells were seeded in a 12-well multiwell in transwell inserts
(PET membrane, 0.4μm pore size, 1.12 cm2 surface area) at
2:6 × 105 cells/cm2 and maintained for 21 days in complete
medium. The medium was changed every second day. By
21 days, the monolayers become completely differentiated.
The integrity of the monolayers was evaluated by mea-
surement of the transepithelial electrical resistance (TEER)
using an EVOM2 epithelial voltohmmeter (World Precision
Instruments, Sarasota, FL, USA). Only monolayers showing
TEER higher than 300Ω × cm2 were then used for transport
experiments. The integrity of the monolayers was checked
before, during, and after the experiment. The filters were
washed for 15-20min at 37°C adding prewarmed Hank’s
balanced salt solution buffered with 25mM HEPES and
NaHCO3 (0.35 g/L) at pH7.4 to the apical (0.4mL) and to
the basolateral (1.2mL) transwell compartments, as previ-
ously described [27]. For transport experiments, donor
solution containing BRP2 peptide at the desired concentra-
tion (100-1μM) was added to the apical compartment for
the apical to basolateral (absorptive) direction. Samples from
the receiving compartment were collected at different time
points up to 120min (15, 30, 60, 90, and 120min). Samples
from the donor compartment were collected at time 0 and
at the end of the experiment (120min) for the calculation
of the mass balance.
Samples were stored at −20°C until UHPLC-MS/MS
analyses to measure the concentration of BRP2 in both
compartments (for detailed conditions, see Supporting Infor-
mation Appendix S2).
The apparent permeability coefficient (Papp) was
calculated as described according to
Papp =
dMR tð Þ
dt
× 1
A × CD0
, ð1Þ
where MR is the amount of substance in the receiver cham-
ber, A (cm2) is the surface area of the barrier, and CD0
(μM) is the initial donor concentration. The reduction in
donor concentration was also taken after every sampling
(see Supporting Information Appendix S3) [28].
2.5.2. Immunofluorescence Analysis on Caco-2 Cell
Monolayers. The transwell membranes from TEER experi-
ments were washed with PBS and fixed with 4% parafor-
maldehyde (PFA) for 15min. Membranes were then
washed in PBS and blocked with blocking solution (0.1%
Triton, 1% BSA, 0.02% sodium azide, and 50mM ammo-
nium chloride) for 20min at room temperature in the dark.
Afterwards, they were incubated with an anti-zonulin 1 anti-
body (#402200, Invitrogen, Thermo Fisher Scientific, Wal-
tham, MA, USA) at the final concentration of 2μgmL-1 at
room temperature for 2 hours. Immunofluorescence staining
was obtained by incubating the membranes for 90min with
Alexa Fluor 488 donkey anti-rabbit IgG (#A31573) at the
final concentration of 4μgmL-1 (Invitrogen). The nuclei
were counterstained with DAPI (1 : 2000). Membranes were
cut down with an operating knife blade along the margin of
the chamber and were mounted on slides using VectaMount
solution (AQ Vector Laboratories, Burlingame, CA, USA).
Slides were examined under a Nikon fluorescence inverted
microscope (Nikon Instruments Europe, Firenze, Italy) and
then analyzed through ImageJ software as previously
described [29].
2.6. Vascular Reactivity Studies. Second-order branches of
the mesenteric arterial tree (internal diameter between 150
and 250μm) were dissected and mounted on a wire
myograph as previously described [30]. Briefly, vessels were
equilibrated for 60min at 45mmHg intraluminal pressure
in warmed oxygenated (95 : 5%, air : CO2) Krebs solution
(pH7.4) containing the following (mmol L-1): 120 NaCl, 25
NaHCO3, 4.7 KCl, 1.18 KH2PO4, 1.18 MgSO4, 2.5 CaCl2,
0.026 EDTA, and 5.5 glucose. Media and lumen diameters
were measured with a computer-based video imaging system
(Danish Myo Technology). Endothelium-dependent and
endothelium-independent relaxation was assessed by
measuring the dilatory responses to cumulative doses of
acetylcholine (Ach, 10-9 to 10-5mol L-1) or nitroglycerine
(Nitro, 10-9 to 10-5mol L-1), respectively, in vessels precon-
tracted with phenylephrine (10-9 to 10-5mol L-1). After
evaluation of basal vascular function, we have tested the effect
of peptide on angiotensin II-induced vasoconstriction (Ang
II, 10-9 to 10-5mol L-1), preincubating the vessels with
different dosages of BRP2 (100-1μmol L-1).
2.6.1. Dihydroethidium (DHE) Staining. DHE was used to
evaluate the levels of oxidative stress in mouse mesenteric
arteries as previously described [31]. Briefly, vessels were
stained with 5mol L-1 DHE for 20min, then mounted
and observed under a fluorescence microscope (Zeiss,
Oberkochen, Germany). Images were acquired by a digital
camera system.
2.6.2. NADPH Oxidase Activity Measurement. NADPH
oxidase (NOX) activity in a pool of mesenteric arteries was
measured in untreated cells and cells treated with angiotensin
II and preincubated with BRP2 plus Ang II as previously
described [31]. In another experimental set, we measure
NADPH oxidase activity in IEC-6 cells following the same
protocol but using 150μg of protein extract. Vessels were
placed in a chilled modified Krebs/HEPES buffer. Periadven-
titial tissue was carefully removed, and the vessels were
repeatedly washed to remove adherent blood cells. A 10%
vessel homogenate was prepared in 50mmol L-1 phosphate
buffer containing 0.01mmol L-1 EDTA. The homogenate
was then subjected to low-speed centrifugation (1000 g) for
10min to remove unbroken cells and debris. 20μL was added
to glass scintillation vials containing 5μmol L-1 lucigenin in
1mL phosphate buffer. The chemiluminescence that
occurred over the ensuing 5min in response to the addition
of 100μmol L-1 NADPH was recorded (Beckman LS6500
Multipurpose Scintillation Counter; Beckman Coulter,
Fullerton, CA). In preliminary experiments, homogenates
alone without the addition of NADPH gave only minimal
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signals. Furthermore, NADPH did not evoke lucigenin
chemiluminescence in the absence of homogenate.
2.6.3. Immunoblotting and Nuclear/Cytoplasmic
Fractionation. Immunoblots were performed as previously
described [32]. Briefly, 30μg tissue extract for each sample
was separated by SDS-PAGE and transferred onto a nitrocel-
lulose membrane. Blocked membranes were incubated with
primary antibodies in TBS-Tween and 5% milk overnight.
Blocked membranes were then incubated with anti-MnSOD
(1 : 1500) and anti-β-actin (1 : 1000).
Nuclear and cytoplasmic fractions, obtained as previ-
ously described [32], were separated by SDS-PAGE and
transferred onto nitrocellulose membranes [32]. Blocked
membranes were incubated with anti-Nrf2 (1 : 2000), anti-
GAPDH (glyceraldehyde 3-phosphate dehydrogenase,
1 : 3000), and anti-HDAC2 (histone deacetylase 2, 1 : 2000)
overnight and then detected using an appropriate horserad-
ish peroxidase-coupled secondary antibody (Millipore,
Milan, Italy) and visualized with enhanced chemilumines-
cence. The purity of nuclear and cytoplasmic fractions was
confirmed using anti-HDAC2 and anti-GAPDH, respec-
tively. Immunoblotting data were analyzed using ImageJ
software (developed by Wayne Rasband, National Institutes
of Health, USA) to determine OD of the bands. The OD
reading was normalized to account for variations in loading.
2.6.4. Ras-Related C3 Botulinum Toxin Substrate 1- (Rac1-)
GTP Pull-Down Experiments. Mesenteric arteries were lysed
in a buffer containing NP-40 equipped with kit STA-401-1
(Cell Biolabs Inc., San Diego, CA). The p21-binding domain
of p21-activated protein kinase bound to agarose beads was
added, and active Rac1, binding to PAK1, was separated by
repetitive centrifugation and washing. Then, the specimens
were boiled in Laemmli buffer and subjected to SDS-PAGE,
and Rac1 was quantified by immunoblot analysis. In detail,
Rac1-GTP was detected with the monoclonal antibody anti-
Rac1-GTP c (1 : 800; STA-401-1, Cell Biolabs Inc.) and total
Rac1 with monoclonal anti-Rac1 (1 : 1000; Abcam). The
amount of Rac1-GTP was normalized to the total amount
of Rac1 in tissue lysates for the comparison of Rac1 activity
(GTP-bound Rac1) among different samples.
2.7. Data Analysis. Data were reported as mean ± standard
errormean values, of at least three independent experiments,
each in triplicate. In order to analyze the effects of our treat-
ments on increasing doses of acetylcholine, we performed a
2-way repeated measures ANOVA with the Bonferroni post
hoc test for multiple comparisons. Statistical analysis was
performed by analysis of the variance test, and multiple
comparisons were made by the Bonferroni test. A p value less
than 0.05 was considered significant.
3. Results
3.1. Antioxidant Effect of BRP2 on ROS Release in IEC-6 Cells
Treated with H2O2. With the aim of investigating the poten-
tial of buffalo ricotta cheese against oxidative stress induced
by H2O2 in IEC-6 cells, the intracellular ROS production
was measured. The GI digest of buffalo ricotta cheese was
separated into two different fractions BRF1 and BRF2 by
Semiprep-RPLC (Figure 1(a)).
No cytotoxic effect was observed when IEC-6 cells were
treated with BRF1 and BRF2 fractions (data not shown).
On the other hand, both tested fractions significantly reduced
ROS release in a concentration-dependent manner (p < 0:05
vs. H2O2; Figure 1(b)), with BRF2 fraction showing higher
efficacy (p < 0:01 vs. BRF1; Figure 1(b)).
Thus, we focused on the identification of most abundant
peptides of this fraction by UHPLC-PDA-MS/MS analysis.
An intense peak in BRF2 was selected and identified as
BRP2 (Figure 2(a)), namely, Ser-Phe-Asn-Pro-Thr-Gln-Leu
(β-LG, f168-174, and SFNPTQL, Figure 2(b)). The relative
amount of the peptide was calculated by MS/MS in 1mg of
BR digest and BRF2 (14:73 ± 0:38% μM and 33:48 ± 0:56 μ
M, respectively).
To investigate its biological properties, the peptide was
synthesized by an Fmoc solid-phase approach (see
Supporting Information Figure S1). Finally, the
antioxidant potential of BRP2 was tested in IEC-6 cells
treated with H2O2. Our results showed that BRP2 caused, at
all tested concentrations (100-1μM), a significant decrement
of ROS release induced by H2O2 (1mM; p < 0:01 vs. H2O2,
Figure 2(c)), thus exerting a cytoprotective effect against
induced oxidative stress.
3.2. Evaluation of BRP2 Bioavailability. To assess BRP2
bioavailability, its transmembrane permeability was
evaluated through Caco-2 fully differentiated cell monolayers
[28]. As shown in Figure S2 (see Supporting Information),
the transport amounts of BRP2 increased approximately
linearly, in a time- (0-120min) and concentration-
dependent (1-100μM) manner.
BRP2 showed moderate transport due to Papp values,
ranging from 0.20 to 0:53 × 10–6 cm/s (see Supporting
Information Table S1). Finally, the Papp of BRP2 in the
apical to basolateral direction (A-B), as well as that in
the basolateral to apical direction (B-A), was compared to
explore the possible transport mechanism. In particular, the
efflux ratio, defined as the quotient of the secretory
permeability and the absorptive permeability (B-A/A-B),
was less than 1 suggesting that passive diffusion could be the
main intestinal transport mechanism of BRP2 [33].
Moreover, in order to evaluate the effects of BRP2 on Caco-2
monolayer integrity and cell vitality, we performed
immunofluorescence analysis on transwell inserts at the end
of transport studies. As shown in Figure S3 (see Supporting
Information), Caco-2 cell monolayer integrity was preserved
upon BRP2 treatment at all the concentrations tested as
confirmed by tight junction protein zonulin-1 expression
(green) and cell vitality.
3.3. BRP2 Reduces Angiotensin II-Induced Vasoconstriction
and Oxidative Stress in the Mouse Mesenteric Artery. In order
to investigate the antioxidant capability of BRP2 also in
ex vivomodel able to reproduce the cardiovascular condition
of the vascular system, we performed experiments on the
mouse mesenteric artery that is considered the prototype of
resistance vessels involved in the modulation of systemic
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hemodynamic parameter. Interestingly, the preincubation of
mesenteric arteries with increasing doses of BRP2 showed a
progressive dose-dependent reduction of Ang II-induced
vasoconstriction (Figure 3(a)), with maximal effects at
100μM, with a reduction of the Ang II-vasoconstrictive
response of about 92:0 ± 4:0% (Figure 3(b)). This functional
effect drove us to explore its action on the oxidative stress
status, since oxygen-derived free radicals are selectively
involved in the vascular response to Ang II. By DHE staining,
we showed that BRP2 specifically reduces the Ang II-induced
ROS production (Figure 3(c)). To support this effect, the
measurement of NOX activity revealed that BRP2 is capable
of markedly attenuating the lucigenin signal in a dose-
dependent manner (Figure 3(d)).
3.4. Antioxidant and Hypotensive Effects of BRP2. The endog-
enous antioxidant system mainly consists of intracellular
enzymatic antioxidants that are responsible for redox
homeostasis balance. Nrf2 is an intracellular transcription
factor that regulates the expression of several genes to
activate antioxidative enzymes and detoxifying factors [34].
For these reasons, in order to give an insight into the molec-
ular mechanisms underlying the antioxidant effects of BRP2,
its influence on this specific antioxidant pathway was studied.
As shown in Figure 4(a), nuclear Nrf2 levels are
increased in IEC-6 cells treated with BRP2 (50μM)+H2O2
(1mM), with respect to H2O2 alone. It is known that Nrf2
activation leads to the expression of cytoprotective
enzymes. In our experimental model, the effect of BRP2
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on HO-1, NQO1, and SOD enzymatic expression was
assessed. We observed that the expression of cytoprotective
enzymes was significantly enhanced in the presence of
H2O2 (1mM; p < 0:001 vs. control). Administration of
BRP2 (100-1μM) further increased HO-1 (p < 0:001 vs.
H2O2; Figure 4(b)), NQO1 (p < 0:001 vs. H2O2;
Figure 4(c)), and SOD expression (p < 0:001 vs. H2O2;
Figure 4(d)). Nrf2 is generally held in the cytoplasm as an
inactive complex bound to a repressor molecule and sensor
of intracellular redox state. We found that in a time-
dependent manner, BRP2 is able to induce Nrf2 transloca-
tion to the nucleus, where it turns active. Already starting
from 1 hour of treatment, it is possible to appreciate the
translocation of this factor that becomes maximal after 6
hours from BRP2 treatment (Figure 5(a)). Moreover, associ-
ated with the Nrf2 translocation, it was possible to note that
at 1 hour there was an increase in MnSOD expression
(Figure 5(b)).
It is well known that Ang II-induced ROS production
is mainly mediated by NADPH oxidase activation, a
multimeric complex that requires the small GTPase Rac1
to become active. Some studies have reported the func-
tional and mechanistic connection between Rac1 and the
transcription factor Nrf2. Based on these evidences, using
the pull-down assay, we found a 50% reduction of Rac1-
GTP after 1 hour of BRP2 treatment that further reduces
up to six hours, thus supporting the capability of BRP2
to inhibit the angiotensin II-induced ROS production
through NADPH oxidase recruitment inhibiting Rac1
activation (Figure 5(c)).
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Figure 3: (a) Vascular responses to increasing doses of angiotensin II (10-9 to 10-5) of mouse mesenteric arteries preincubated with increasing
doses of BRP2 (1, 10, 50, and 100 μM). (b) Bar graph of the last time point of dose-response curve to angiotensin II (10-5M). (c) In situ
detection of superoxide generation with DHE staining in segments of mesenteric arteries treated with Ang II (10-5M) alone or plus BRP2
(100 μM). Scale bar: 50 μm. (d) Graphs of superoxide production in mesenteric arteries measured continuously in the presence or absence
of BRP2 by using 5 μmol L-1 lucigenin-enhanced chemiluminescence. Values aremean ± s:e:m:, expressed as RLU/(s·mg dry weight) (n = 4).
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4. Discussion
In our previous study, the peptidomic profile of six differ-
ent commercial dairy products based on buffalo milk was
highlighted, revealing the presence of numerous peptides
with immunomodulatory, antihypertensive, antioxidant,
antimicrobial, anticancer, and antidiabetic properties [17].
However, only one-third of the identified peptides showed
a recognized biological activity. Based on this data, we
started a rational biological characterization of the six
selected commercial products [18]. Buffalo ricotta cheese
showed the highest antioxidant activity, compared to the
other investigated buffalo dairy products. The peptidomic
approach led to the identification of an abundant peptide,
corresponding to the fragment 60-72 of β-lactoglobulin,
namely, BRP, with interesting antioxidant activity [18].
With respect to the previous study, based on ultrafiltration
with different cut-off membranes, in the present study, we
fractionated the entire buffalo ricotta cheese digest by
semipreparative liquid chromatography. Two main frac-
tions were obtained in the most active fraction, and abun-
dant β-lactoglobulin peptides (f168-174, SFNPTQL, and
BRP2) were detected. The antioxidant potential of this
peptide was not reported so far (see Supporting Informa-
tion Appendix S4); thus, we focused on its possible
potential against oxidative stress, in particular on its ability
to decrease ROS release. The intestine is the main organ of
exposure and/or absorption of nutrients, toxic food con-
taminants, and metabolic products coming from the intes-
tinal bacteria. The alteration of the integrity and function
of the intestinal epithelium produces a negative impact
on the rest of the body [35]. In many cases, the intestine
responds adequately against the oxidative stress, but aging
or disequilibrium in the redox state of the gut can induce
intestinal pathologies such as inflammatory bowel disease,
gastroduodenal ulcers, and colon cancer [36].
Our results showed that β-lactoglobulin-derived peptide
BRP2 reduced ROS release induced by H2O2 in IEC-6 cells.
Interestingly, BRP2 possessed a discrete bioavailability,
showing a moderate absorption through a fully differentiated
Caco-2 intestinal monolayer, without affecting its integrity
and tight junction zonulin-1 protein expression.
To understand the antioxidant effect of BRP2 peptide, its
molecular basis was investigated.
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Figure 4: (a) Effect of BRP2 on Nrf2 nuclear translocation (scale bar: 10μm). Blue fluorescence and green fluorescence indicate localization of
the nucleus (DAPI) and Nrf2, respectively. Effect of BRP2 on (b) HO-1, (c) NQO1, and (d) SOD expression in the IEC-6 cells, evaluated by the
cytofluorimetric technique. Values,mean ± s:e:m:, are expressed as % of inhibition of HO-1, NQO1, and SOD expression vs. H2O2. °°° denotes
p < 0:001 vs. control. ∗∗∗ denotes p < 0:001 vs. H2O2.
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Nrf2 is a transcription factor that plays a central role in
the regulation of antioxidant and phase 2 detoxifying
enzymes and related proteins [37]. An increase in intracellu-
lar ROS enhances nuclear translocation of Nrf2 and expres-
sion of its target genes such as HO-1, NQO1, and SOD [38,
39]. Our results indicated that BRP2 protects intestinal epi-
thelial cells from oxidative stress by ROS release inhibition
and by upregulation of cytoprotective enzymes via the
Nrf2/ARE pathway.
An oxidant mechanism of BRP2 could be related to the
presence of amino acidic residues such as proline and threo-
nine in its primary sequence as previously reported for β-lac-
toglobulin and β-casein peptides [18, 40].
A growing body of evidence indicates that an imbalance
between endogenous reactive oxygen species and antioxi-
dants in favor of the former contributes markedly to vascular
dysfunction [41]. Based on the local antioxidant properties
and on the moderate intestinal permeation of BRP2, we
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Figure 5: (a) Representative immunoblot from the pull-down assay of mouse mesenteric arteries for active Rac1 (Rac1-GTP). (b)
Immunoblot analysis for Nrf2. Cytoplasmic (Cyto) and nuclear (Nuc) fractions were prepared from untreated mouse mesenteric arteries
or treated with BRP2. GAPDH and HDAC2 were used as cytoplasmic and nuclear markers, respectively. Right: nuclear/cytoplasmic ratios
for Nrf2 are plotted from densitometry (n = 3). (c) Representative immunoblot for MnSOD in mouse mesenteric arteries treated with
BRP2 (100 μM) and Ang II (10-5M) (n = 3).
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decided to investigate its potential systemic effects in an
ex vivo mouse model of vascular reactivity. The most impor-
tant endogenous bioactive octapeptide that exerts a potent
vasoconstrictor through ROS production, modulating
systemic hemodynamic parameters, is represented by Ang
II. Our studies clearly demonstrated that pretreatment with
BRP2 inhibits the Ang II-derived vasoconstrictive responses
of mouse mesenteric arteries, in a dose-dependent manner.
The 90% of inhibition after the exposure to the maximal dose
of the peptide was obtained. This potent effect evoked by
BRP2 is strictly related to its antioxidant properties, counter-
acting the oxidative stress induced by Ang II. In this regard,
several evidences suggest that NAD(P)H oxidase is a major
source recruited by Ang II to induce ROS generation in the
vascular wall [42]. The evaluation of NADPH oxidase activity
revealed a significant reduction of enzymatic activity after
pretreatment with BRP2.
NOX is a multisubunit enzyme complex that requires
specific interactions with a plethora of molecules. In this
regard, the small GTPase Rac1 is essential for the correct
assembly of NADPH subunits and their activation [43].
The treatment of mesenteric arteries with BRP2 significantly
reduces Rac1 activation, supporting the effect of the peptide
on the reduction of NADPH oxidase activity and the reduc-
tion of vasoconstrictive responses to Ang II. These ex vivo
results demonstrate that BRP2 is able to act on two concom-
itant mechanisms, the reduction of the active form of Rac1
with a consequent reduction of NOX activity and the induc-
tion of nuclear translocation of Nrf2 that is pivotal in cellular
defense against oxidative stress [44].
5. Conclusions
In conclusion, the results obtained highlight the important
role of BRP2 in intestinal and cardiovascular protection, both
inhibiting ROS release and enhancing an important antioxi-
dant response consisting of Nrf2 pathway activation and
cytoprotective enzyme expression. The antioxidant effects
evoked in mice mesenteric arteries suggest BRP2 as a novel
peptide candidate with promising cardiovascular effects and
pave the way to its in vivo characterization in a model of car-
diovascular disease.
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